ResMed Delivers Record Q4 Revenue as FY2026 Earnings and Cash Generation Strengthen
ResMed Inc. (ASX: RMD) delivered a strong finish to FY2026, with fourth-quarter revenue increasing 9% to a record US$1.5 billion, supported by sustained demand for its sleep and breathing health portfolio and continued global execution. Non-GAAP diluted EPS increased 16% to US$2.95, while FY2026 revenue advanced 10% to US$5.7 billion. Full-year non-GAAP gross margin expanded 240 basis points to 62.4%, while non-GAAP operating margin improved 180 basis points to 36.1%, highlighting stronger operating leverage. ResMed generated US$1.8 billion in operating cash flow and US$1.6 billion in free cash flow during FY2026, supporting more than US$1.0 billion of shareholder returns. Looking ahead, the company intends to return more than US$1.85 billion through dividends and share repurchases in FY2027 and increased its quarterly dividend by 10% to US$0.66. Strategic progress also included the Noctrix Health acquisition, planned MatrixCare divestment and continued product expansion across global markets.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
ResMed Delivers Record Q4 Revenue as FY2026 Earnings and Cash Generation Strengthen
ResMed Inc. (ASX: RMD) delivered a strong finish to FY2026, with fourth-quarter revenue increasing 9% to a record US$1.5 billion, supported by sustained demand for its sleep and breathing health portfolio and continued global execution. Non-GAAP diluted EPS increased 16% to US$2.95, while FY2026 revenue advanced 10% to US$5.7 billion. Full-year non-GAAP gross margin expanded 240 basis points to 62.4%, while non-GAAP operating margin improved 180 basis points to 36.1%, highlighting stronger operating leverage. ResMed generated US$1.8 billion in operating cash flow and US$1.6 billion in free cash flow during FY2026, supporting more than US$1.0 billion of shareholder returns. Looking ahead, the company intends to return more than US$1.85 billion through dividends and share repurchases in FY2027 and increased its quarterly dividend by 10% to US$0.66. Strategic progress also included the Noctrix Health acquisition, planned MatrixCare divestment and continued product expansion across global markets.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au